Evidence gap analysis
Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation
Recent news and posts
Merged 2024 RIHN and Supplementary list for IVD tests published in France
In 2024, the 2023 Repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN List) and Supplementary List of IVD tests were merged.
On July 16, 2024, the merged 2024 List of acts outside the nomenclature (Liste des actes hors nomenclatures, LAHN) financed under MERRI G03 was published by the Ministry of Labor, Health and Solidarity. No new codes were introduced in 2024. The changes concern comments on the four following LAHN codes due to the registration of new indications in the CCAM:
- N504 “EGFR sequencing: 4 exons”;
- N523 “Metastatic colorectal cancer mutational package (KRAS/NRAS) 6 exons”;
- N524 “Metastatic lung adenocarcinoma (EGFR/KRAS) mutational package”;
- N525” Melanoma mutational package (BRAF V600/NRAS)”.
When it concerns acts related to a test for detecting genetic mutations (Companion test), these codes do not need to be coded because the tests are registered in the CCAM.
More details in French can be found here
This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.